Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Blood (2024) 144 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2024-205705

Published: 2024

Journal Articles

Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Selina J Chavda, Marquita Camilleri, Andrew Hall, Laura Clayton, Fatjon Dekaj, Dunsi Bolarinwa, Chantelle Hughes, Doina Levinte, Eileen M Boyle, Martin F Kaiser, Rachel O'Malley, Emma Williams, Andie Guy, Pinkie Chambers, Sandra CM Quinn, Rakesh Popat

Blood (2024) 144 (Supplement 1): 3792.2.

https://doi.org/10.1182/blood-2024-205315

Published: 2024

Journal Articles

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Ceri Bygrave, William Wilson, Rakesh Popat, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Michael A. Chapman, Ruth M de Tute, Selina J Chavda, Elizabeth H. Phillips, Maria del Mar Cuadrado, Fuad Fananapazir, Charlotte Tyson, Sumaiya Kamora, James D. Cavenagh, Roger G Owen, Kwee Yong

Blood (2024) 144 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2024-199514

Published: 2024

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2023-186318

Published: 2023

Journal Articles

Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Blood (2022) 140 (Supplement 1): 10191–10192.

https://doi.org/10.1182/blood-2022-166344

Published: 2022

Journal Articles

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Blood (2022) 140 (Supplement 1): 10106–10107.

https://doi.org/10.1182/blood-2022-169882

Published: 2022

Journal Articles

Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes

Blood (2021) 138 (Supplement 1): 723.

https://doi.org/10.1182/blood-2021-150767

Published: 2021

Journal Articles

Co-Operation of MCL-1 and BCL-X L Anti-Apoptotic Proteins in Stromal Protection of MM Cells from Carfilzomib Mediated Cytotoxicity

Daria Galas-Filipowicz, Selina J Chavda, Jianan Gong, David C.S. Huang, Asim Khwaja, Kwee Yong

Blood (2021) 138 (Supplement 1): 2677.

https://doi.org/10.1182/blood-2021-149160

Published: 2021

Journal Articles

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Blood (2021) 138 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2021-150177

Published: 2021

Journal Articles

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

Blood (2021) 138 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2021-147771

Published: 2021

Journal Articles

Autophagy Blockade Disrupts Myeloma Cell Recovery from Proteasome Inhibition and Enhances Apoptosis

Selina J Chavda, Daria Galas-Filipowicz, Evelyn Fitzsimons, Anna Mikolajczak, Sharon Tooze, Holger W Auner, Katja Simon, Asim Khwaja, Kwee Yong

Blood (2021) 138 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2021-146400

Published: 2021

Journal Articles

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors

Blood (2021) 138 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2021-149027

Published: 2021

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome

Nouf Alrasheed, Lydia Lee, Huw Richards, William Wilson, Oliver C Cohen, MBBS, BSc, FRCPath, Selina J Chavda, Jake Henry, Andrew Furness, Melody Chin, Daria Galas-Filipowicz, Charalampia Kyriakou, Neil K Rabin, Sergio A Quezada, Kwee Yong

Blood (2019) 134 (Supplement_1): 4368.

https://doi.org/10.1182/blood-2019-126682

Published: 2019

Journal Articles

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Selina J Chavda, MBBS, BSc, MRCP, Rachael Pocock, MBBS, BSc, MRCP, Simon Cheesman, BPharm, Emma Dowling, Puneet Verma, MRPharmS, Malcolm Walker, MBBS, MBChB, MD FRCP, Charalampia Kyriakou, MD PhD, Ashutosh D. Wechalekar, Neil K Rabin, MD, Kwee Yong, MD PhD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD

Blood (2018) 132 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2018-99-113832

Published: 2018

Journal Articles

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Selina J Chavda, MBBS BSc MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Pavlina Mesiri, MSc, Nicholas Counsell, Jaimal Kothari, FRCPath, Antonia Bird, Ciaran Mariner, Anastasia Chew, MBBS, MRCP, FRCPATH, Katherine Clesham, MBBS, Sally Moore, BSc, FRPATH, FRCP, MBBS, Laura Percy, MBBS, MRCP, FRCPATH, Ali Rismani, MBBS, Shirley D'Sa, Rakesh Popat, Neil Rabin, Kwee L Yong

Blood (2016) 128 (22): 3465.

https://doi.org/10.1182/blood.V128.22.3465.3465

Published: 2016

Journal Articles

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Melody Chin, BSc, MSc, Jonathan Sive, MBBS, Christopher Allen, BSc, Claire Roddie, MD PhD, Selina J Chavda, MBBS BSc MRCP, Dean Smith, MBBS, Rakesh Popat, Ali Rismani, MBBS, Shirley D'Sa, Neil Rabin, Rosemary E. Gale, PhD BSc, Kwee L Yong

Blood (2016) 128 (22): 4455.

https://doi.org/10.1182/blood.V128.22.4455.4455

Published: 2016

NARROW

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes

Co-Operation of MCL-1 and BCL-X L Anti-Apoptotic Proteins in Stromal Protection of MM Cells from Carfilzomib Mediated Cytotoxicity

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

Autophagy Blockade Disrupts Myeloma Cell Recovery from Proteasome Inhibition and Enhances Apoptosis

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only